adobe stock photos - Sundry Photography The US Roche unit Genentech Inc has signed a US$400 million licence deal with British NativeMS specialist OMass Therapeutics Ltd. Under the exclusive collaboration and licence agreement, Genentech intends to commercialise therapies for inflammatory bowel disease.
Tag Archive for: Genentech
MichaelVi - stock.adobe.comGerman researchers have identified a promising new target to stop the inflammatory response in ulcerative colitis—a breakthrough that could help prevent the progression to colorectal cancer. Phase II clinical trials of a corresponding monoclonal antibody, licensed by Roche, are expected to begin soon.
https://doi.org/10.3390/ijms241411791Genentech, the US subsidiary of Swiss pharmaceutical giant Roche AG, has strengthened the company’s breast cancer pipeline by pre-licensing the global commercialisation rights to Regor Therapeutics’ RGT-419B for US$850m.
Sangamo Therapeutics IncAfter Sangamo Therapeutics Inc. presented an epigenetic ZFN-based repressor at ASGCT 2024 that reduces the expression of the tau protein in the hippocampus by 95% in Alzheimer’s models, Roche’s US subsidiary Genentech has licensed the experimental gene therapy.